• HOME |
  • SITE MAP |
Product Search
since 1897 R&D visual


  • About R&D
  • Research Achievements
  • Organization of research institute
  • Key Research Area
  • R&D Pipeline
  • Technical Innovation Network
  • Global Dong Wha

R&D Pipeline

Type Project Development Stage Characteristic / Advantage
New Drug Ulcerative Colitis
Phase 2a Contributing to an anti-inflammatory effect and the stabilization of intestinal microorganisms
Expect the possibility of remission and the effect of maintenance
Allergic Asthma/Rhinitis
Phase 1 An oral medication with both bronchial inflammation inhibiting and dilating effects
Having superior efficacy in anti-leukotriene and possible steroid combination therapy
IMD Zabolante Non-clinical / Phase 3 Verifying the expansion of pneumonia indication and development possibility of injectable drugs with its excellent antibacterial ability against respiratory infectious and resistant bacteria
Phase 1 A block bust drug complex frequently prescribed in combination to cardiovascular disease patients
Phase 1 A complex to alleviate moderate to severe Alzheimer's disease
Anti-Inflammatory Analgesic drug
Phase 1 Increasing patient convenience by acting on the NSAID-related upper gastrointestinal side effects
Functional Food Cognitive Function Improvement
Clinical trial Developing new lactobacillus (C29, etc.) material to improve cognitive function
Verifying clinical efficacy and safety with aging-friendly functional food
Body Fat Improvement
Clinical trial Developing new lactobacillus (OK67, etc.) materials for body fat improvement
Verifying non-clinical body fat reduction effect and safety
Atopy Improvement
Candidate Safely and effectively improving skin immune function with the raw materials listed in the Korean Food Standards Codex
Go to TOP

6~8F, FastFive Tower, 24, Namdaemun-ro 9-gil, Jung-gu, Seoul, 04522, KOREA

Coptright(c) Dong Wha PHARM.CO.,LTD. All Rights Reserved.